Elevated Levels of Methylmalonate and Homocysteine in Parkinson's Disease, Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis by Levin, Johannes et al.
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Original Research Article 
 Dement Geriatr Cogn Disord 2010;29:553–559  
 DOI: 10.1159/000314841 
 Elevated Levels of Methylmalonate and 
Homocysteine in Parkinson’s Disease, Progressive
Supranuclear Palsy and Amyotrophic
Lateral Sclerosis 
 Johannes Levin  a    Kai Bötzel  a    Armin Giese  c    Michael Vogeser  b    Stefan Lorenzl  a   
 Departments of  a   Neurology and  b   Clinical Chemistry, Klinikum Grosshadern, and  c   Center for Neuropathology and 
Prion Research, Ludwig Maximilians University Munich,  Munich , Germany 
of these diseases. Since elevated levels of both Hcy and MMA 
are neurotoxic, further studies might investigate the effect 
of vitamin therapy on disease progression. 
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 Introduction 
 Amyotrophic lateral sclerosis (ALS), progressive su-
pranuclear palsy (PSP) and Parkinson’s disease (PD) are 
debilitating neurodegenerative disorders that are caused 
by progressive loss of neurons in the central nervous sys-
tem. PD and PSP mainly affect patients between 50 and 
70 years of age  [1, 2] , but ALS can affect individuals as 
young as 20 years of age  [3] . Homocysteine (Hcy) is a
neuro- and vasculotoxic, sulfur-containing intermediary 
product in the methionine cycle. Hcy can be transsulfu-
rated to cystathionine and, subsequently, to cysteine, 
which is a component of glutathione. Hcy can be remeth-
ylated to methionine by the addition of a methyl group 
from 5-methyltetrahydrofolate. Remethylation can be 
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 Abstract 
 Background/Aims: Increasing evidence suggests that ele-
vated levels of homocysteine (Hcy) and methylmalonate 
(MMA) may be involved in the pathogenesis of neurodegen-
erative diseases.  Methods: The urine levels of MMA and se-
rum levels of Hcy as well as folic acid and vitamin B 12 were 
measured in patients suffering from the distinct neurode-
generative diseases progressive supranuclear palsy (PSP), 
amyotrophic lateral sclerosis (ALS) and Parkinson’s disease 
(PD), and compared to age- and gender-matched control 
subjects.  Results: We found significantly elevated concen-
trations of Hcy (PD 15.1, PSP 15.8, ALS 13.9, control 11.2 
  mol/l) and MMA (PD 3.7, PSP 3.1, ALS 3.7, control 1.8 mg/g) 
in all patient groups in comparison with controls. Levels of 
Hcy and MMA did not differ significantly between the neu-
rodegenerative diseases.  Conclusion: Our findings might 
imply that Hcy and MMA are released as a consequence of 
neurodegeneration regardless of the underlying cause and 
serve as surrogate markers of neurodegeneration. Alterna-
tively they might be directly implicated in the pathogenesis 
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catalyzed by methionine synthase, which requires vita-
min B 12 in the form of methylcobalamin as cofactor. 
 Hcy has been found to be elevated in several neurode-
generative diseases such as Alzheimer’s disease and PD 
 [4–6] . In PD, Hcy has been associated with levodopa 
treatment  [7–9] . The Hcy elevation might be explained by 
the methylation of levodopa via catechol-O-methyltrans-
ferase. Catechol-O-methyltransferase, which is present in 
brain and peripheral tissues, releases S-adenosylhomo-
cysteine from levodopa which is subsequently hydrolyzed 
by S-adenosylhomocysteine hydrolase to Hcy ( fig.  1 a). 
This pathway is supported by data that show a normaliza-
tion of Hcy levels secondary to entacapone treatment  [10–
12] . Metabolism of elevated Hcy may take two pathways. 
One possibility involves the methionine synthase which 
catalyzes Hcy in a vitamin B 12 - and methyltetrahydro-
folate-dependent reaction to methionine. Methionine is 
converted to S-adenosyl methionine, which will be a sub-
strate for methylation reactions such as the methylation 
of levodopa. The other possible metabolic pathway is the 
catalyzation of Hcy by the cystathionine   -synthase 
which leads via cysteine to methylmalonate (MMA) and 
succinyl-CoA ( fig. 1 a). Surprisingly, in several recent ar-
ticles, a relationship between levodopa treatment in PD 
patients and elevated Hcy levels could not be found  [13–
15] . In one study, a deficit in folic acid has been found to 
explain Hcy elevation in levodopa-treated PD patients 
 [14] . Therefore, the underlying cause of elevated Hcy in 
PD patients is still under debate. Very recently, it has been 
shown that Hcy is elevated in plasma and cerebral spinal 
fluid of ALS patients  [16, 17] . The levels of Hcy in the 
atypical Parkinson syndrome PSP have not been studied 
before.
 Hcy serum concentrations increase with age as does 
the incidence of neurodegenerative diseases  [18] . Elevated 
levels of Hcy correlate with cognitive impairment and fi-
nally with dementia  [19] . Additionally, a relationship be-
tween Hcy and brain atrophy in elderly individuals has 
been found  [20] . It was demonstrated only recently that 
the reduction of Hcy with folic acid supplementation ef-
fectively improved domains of cognitive function that 
tend to decline with age  [21] . Genetic studies, animal and 
cell culture experiments also support a possible direct in-
volvement of Hcy in neuronal cell death in neurodegen-
erative diseases  [22–24] . Several possible modes of action 
have been discussed  [25, 26] .
 MMA is closely linked to Hcy metabolism ( fig. 1 a). It 
has been demonstrated in vitro that MMA is neurotoxic 
 [27, 28] . Therefore, MMA might be of importance in neu-
rodegenerative diseases in general. Due to its link to Hcy, 
MMA might contribute to the understanding of the role 
of Hcy metabolism disturbances in these diseases. To 
date, little is known about MMA in patients with neuro-
degenerative diseases.
 To shed more light on the role of Hcy and its metabo-
lite MMA in neurodegenerative diseases, we set out to 
study the Hcy and MMA serum concentrations in sev-
eral groups of patients with neurodegenerative diseases 
and in control subjects. To exclude possible confounding 
by vitamin depletion, we checked the levels of vitamin B 12 
and folic acid.
 Materials and Methods 
 Patients 
 Samples of serum and urine from PD patients [n = 41, mean 
age = 66.29 years (range 51–84)], PSP patients [n = 22, mean
age = 66.95 years (range 57–80)], ALS patients [n = 27, mean
age = 66.04 years (range 50–88)] and control subjects [n = 30, 
mean age = 63.79 years (range 42–81)] were collected at the De-
partment of Neurology of the Ludwig Maximilian University Mu-
nich between February 2005 and June 2008. Diagnosis of ALS was 
based on clinical and electrophysiological criteria, diagnosis of 
PSP was based on clinical and PET diagnostics  [29] , and diagnosis 
of PD was based on UK Brain Bank criteria  [30] . PD patients were 
treated with steady doses of levodopa ranging from 150 to 750 mg 
per day ( table 1 ). None of the PSP patients or the ALS patients re-
ceived levodopa. Control subjects were free of neurological ill-
ness. Patients and controls did not take supplementary vitamins. 
 Following informed consent, 10 ml of blood were collected by 
venipuncture and 10 ml of urine were collected as well. The pa-
tients had no evidence of urinary tract infections at the time of 
sampling. Blood and urine samples were taken on working days 
between 9 a.m. and 12 p.m. from fasting patients. The samples 
were immediately sent on ice to the laboratory and analyzed at 
once at the Department of Clinical Chemistry. All experimental 
procedures were performed by individuals blinded to sample 
identity and diagnosis. This study followed the rules of the Dec-
laration of Helsinki.
 Analytical Methods 
 Serum concentrations of vitamin B 12 and folic acid, and plas-
ma concentrations of Hcy were determined using automated li-
gand-binding assays [Roche Elecsys for vitamin B 12 and folic acid 
(Roche Diagnostics, Mannheim, Germany); Bayer Centaur for 
Hcy (Bayer Vital, Fernwald, Germany)]. Urinary MMA was de-
termined using isotope dilution gas chromatography/mass spec-
trometry after extraction and derivatization with threefold deu-
terated MMA as the internal standard  [31, 32] . For the quantifica-
tion of Hcy and urinary MMA, respectively, intra- and interassay 
coefficients of variation below 10% were observed for quality con-
trol samples in the clinically relevant concentration range. MMA 
concentrations in urine are higher than in serum, which supports 
analysis in urine  [31] . MMA in urine is largely dependent on cre-
atinine levels in urine  [31, 32] . Urinary creatinine was analyzed 
using the photometric Jaffé method in order to calculate the uri-
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 Fig. 1.   a Hcy metabolism and its con-
nection to levodopa ( L -dopa) and MMA.
 b Concentrations of folic acid, vitamin B 12 
and Hcy in serum and MMA/creatinine 
ratio in urine. The patient groups of PD, 
PSP and ALS had significantly higher Hcy 
serum concentrations and higher MMA/
creatinine ratio in urine compared to con-
trol subjects. COMT = Catechol-O-meth-
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nary MMA/creatinine ratio. Whereas serum or plasma MMA 
concentrations are increased in the case of impaired renal func-
tion, the urinary MMA/creatinine ratio is a more robust param-
eter for the assessment of the cobalamin status on the tissue level 
which is less dependent on changes in renal function  [33] . Fur-
thermore, measurement of MMA in urine is more robust com-
pared to measurement in serum because the analytic concentra-
tions are several-fold higher.
 Statistical Analysis 
 Statistical analysis of laboratory data such as folic acid, vitamin 
B 12 and Hcy serum levels as well as the MMA/creatinine ratio in 
urine was performed by ANOVA using SigmaStat 3.5 (Systat Soft-
ware, Chicago, Ill., USA). Possible differences between the two 
groups (age, levodopa doses, duration of disease and urine creati-
nine concentration) were checked for significance. Prior to testing, 
normal distribution of data was confirmed using Lilliefors testing. 
Data are indicated as mean values  8 standard deviation.
 Results 
 Patients 
 Prior to data analysis, 6 PD patients and 5 control sub-
jects were excluded due to incomplete data collection. 
Furthermore, elevated creatinine levels ( 1 2.1 g/l) led to 
the exclusion of 4 PD patients and 1 control subject be-
cause these levels indicated limited renal function which 
interferes with levels of MMA and Hcy  [33] . One PD pa-
tient, 4 PSP patients and 7 ALS patients were excluded 
due to folic acid or vitamin B 12 deficiency. Folic acid de-
ficiency and vitamin B 12 deficiency were defined as values 
below the lower level of normal ( fig. 1 b). However, it has 
to be stated that neither the Hcy nor the MMA levels of 
the excluded patients significantly exceeded the levels
of the tested patient population (online suppl. figure 1, 
www.karger.com/doi/10.1159/000314841). 
 The basic characteristics of the participants are sum-
marized in  table 1 . There were no statistical differences 
between the patient groups and control subjects with re-
gard to age and urine creatinine concentrations (p = 0.32, 
p = 0.22, p = 0.37; p = 0.18, p = 0.44, p = 0.37). The mean 
dose of levodopa in the PD patient group was 466 mg/day.
 Levels of Vitamin B 12 and Folic Acid 
 The vitamin B 12 and folic acid serum concentrations 
did not differ significantly between the patients and con-
trol subjects (vitamin B 12 : p = 0.12; folic acid: p = 0.41; 
 fig. 1 b).
 Determination of Hcy in Serum 
 Hcy measurements in serum showed that control sub-
jects had a mean level of 11.19  8 1.21   mol/l. PD patients 
showed significantly increased concentrations of Hcy 
(15.05  8 4.63   mol/l) in comparison with the control 
subjects (p  ! 0.001;  fig. 1 b). Levels of Hcy were also sig-
nificantly (p  ! 0.001) elevated in PSP (15.75  8 5.75 
  mol/l) and ALS patients (13.94  8 3.47   mol/l). There 
was no statistical difference between Hcy values of levo-
dopa-treated PD patients and the patient groups with 
other neurodegenerative diseases.
 Determination of MMA in Urine 
 Although we generally found the same differences for 
all groups at similar levels of significance using determi-
nation of MMA concentrations in urine, in this work we 
present data for the more robust MMA/creatinine ratio. 
The MMA/creatinine ratio was significantly increased in 
the urine of PD patients as compared to the control sub-
jects (3.71  8 2.30 mg/g vs. 1.76  8 0.73 mg/g; p  ! 0.001; 
 fig. 1 b). The MMA/creatinine ratio was also found to be 
significantly elevated in the PSP and ALS patients. The 
mean values of MMA for PSP and ALS patients were 3.19 
 8 1.66 mg/g and 3.70  8 2.25 mg/g, respectively. No sta-
tistically significant differences were observed in the 
MMA/creatinine ratio between levodopa-treated PD pa-
tients and the other patient groups.
Table 1.  Demographic and treatment characteristics of patient and control groups
PD patients PSP patients ALS patients Control subjects
Number (analyzed) 41 (30) 22 (18) 27 (20) 30 (24)
Age, years 66.2987.69; 51–84 66.9585.71; 57–80 66.0487.45; 50–88 63.62811.32; 42–81
Women/men 14/17 10/12 8/19 12/13 
Levodopa, mg/day 4668173; 150–900 – – –
Creatinine in urine, g/l 0.9380.48; 0.3–1.5 0.8780.42; 0.3–1.4 0.8880.49; 0.2–1.7 0.7780.41; 0.2–1.5
V alues are given as means 8 SD and ranges where applicable.
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 Discussion 
 Previous studies have analyzed single neurodegenera-
tive diseases and have found elevated levels of Hcy  [7, 9, 
12, 16, 17, 34] . Some data suggest that MMA may also be 
elevated and these data are mainly available for PD pa-
tients  [34] . The present study investigated Hcy and MMA 
levels in PD, PSP and ALS patients without vitamin B 12 
and folic acid deficiency and shows that both are elevated 
in the three distinct neurodegenerative disorders without 
obvious differences between the diseases. This might im-
ply that Hcy and MMA are either directly involved in the 
neurodegenerative process or that both might be a sur-
rogate marker for neurodegenerative processes (e.g. re-
leased from dying cells). However, it must be noted that 
the determination of Hcy and MMA in serum and urine, 
respectively, does not necessarily allow direct conclu-
sions to be drawn with regard to the brain levels of MMA 
and Hcy as both can be generated outside the central ner-
vous system as well. 
 The role of Hcy in neurodegenerative diseases is sup-
ported by various findings. It has been shown that ele-
vated serum levels increase the risk for neurodegenera-
tive diseases  [35] . Furthermore, an association of more 
rapid disease progression for PD patients with increased 
Hcy levels  [6] and an association of Hcy with the pro-
gression of mild cognitive impairment to dementia have 
been shown  [19] . Hcy is also elevated in patients with 
manifest Alzheimer’s disease  [9] . Very recently, Hcy has 
also been found to be elevated in plasma and cerebral 
spinal fluid of ALS patients. The authors speculated 
about a possible implication in the pathogenesis of ALS 
 [16, 17] . 
 Genetic, animal and in vitro studies support the po-
tential relevance of Hcy in neurodegenerative diseases. 
Mutations in the methylenetetrahydrofolate reductase 
gene (T/T genotype) encoding for enzymes of the Hcy 
metabolism have been identified as a risk factor for PD 
 [22] . Some findings suggest that Hcy may play an active 
role in neurodegeneration. Administration of Hcy in a 
mouse model of PD resulted in the death of dopaminergic 
cells  [23] . Elevated levels of Hcy increase the vulnerabil-
ity of hippocampal neurons to excitotoxic and oxidative 
injury in cell culture and in an animal model  [28] . Direct 
neurotoxicity of Hcy to neuronal cells has been demon-
strated  [24] . Several mechanisms by which Hcy induces 
neurotoxicity like excitotoxicity by stimulating NMDA 
receptors  [25] , increased production of   -amyloid aggre-
gates, promotion of neuronal apoptosis  [26] and an in-
crease of oxidative stress  [36] have been suggested. Re-
gardless, elevated serum levels of Hcy expose patients to 
an increased risk of arteriosclerosis  [35] .
 Not only Hcy but also levels of MMA and MMA/cre-
atinine ratio in the urine of PD, PSP and ALS patients are 
significantly elevated ( fig. 1 b). Taken together with ele-
vated Hcy this might imply that the whole metabolic cycle 
involving S-adenosylhomocysteine, Hcy, cysteine, and 
MMA is altered in neurodegenerative diseases ( fig. 1 a). In 
subjects with normal renal function, elevated levels of 
MMA usually indicate vitamin B 12 deficiency  [33] , be-
cause MMA is released in a vitamin B 12 -dependent reac-
tion from cysteine in the transsulfuration pathway  [37] . 
This also applies to vitamin B 12 -deficient, levodopa-treat-
ed PD patients  [34] . Because of the important influence 
of vitamin B 12 on the metabolism of MMA we monitored 
the levels of these vitamins in all groups and excluded 
patients with vitamin B 12 and folic acid values below the 
normal range. We furthermore checked renal function as 
a possible interfering factor and excluded patients with 
indications of renal impairment ( table 1 ). According to 
well-known metabolic pathways ( fig.  1 a), a causal con-
nection between Hcy and MMA elevations is likely. Hcy 
accumulation provides an increased amount of substrate 
for the cystathionine   -synthase, consequently leading to 
elevated MMA ( fig. 1 a). MMA has been shown to be an 
endogenous cellular mitochondrial inhibitor and neuro-
toxin. When injected into the basal ganglia of the adult 
rat brain it produced dose-related cell death in the sub-
stantia nigra  [27] . The neuronal damage caused by MMA 
has been suggested to involve inhibition of complex II 
and the mitochondrial creatine kinase  [27, 38] . Recently, 
a relationship between MMA and markers of methyla-
tion and pathological findings of the substantia nigra and 
neurodegeneration was also found  [39] . Whether it is suf-
ficient to reduce Hcy in order to achieve reduced MMA 
levels, or whether a direct intervention in the MMA me-
tabolism, for example by vitamin B 12 , is necessary, re-
mains to be determined.
 Although the neurodegenerative disorders which were 
investigated in our study have different pathological 
mechanisms, a significant number of patients will devel-
op dementia during the course of these diseases. Since 
Hcy has even been shown to be elevated in Alzheimer’s 
disease patients  [9, 21, 25] , it might be a risk factor for de-
velopment of dementia regardless of the underlying dis-
ease.
 Several studies show that elevated levels of Hcy in PD 
are related to levodopa treatment  [6, 8, 10–12] . We found 
elevated levels of Hcy and MMA in a similar range in all 
patients investigated regardless of levodopa treatment. 
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Further studies are needed to determine if the elevation 
of Hcy and MMA as observed in Alzheimer’s disease, PSP 
and ALS can also be found in levodopa-naïve PD patients 
at some stages of the disease.
 Although vitamin levels are normal in neurodegen-
erative diseases, vitamin treatment of patients might lead 
to normal Hcy and MMA levels if additional vitamin B 12 
and folic acid enabled the methionine synthase to cata-
lyze the reaction of Hcy to methionine ( fig. 1 a). An addi-
tional need for B vitamins has been reported previously 
for PD patients  [40] . Further studies are needed to inves-
tigate this effect and whether vitamin treatment might be 
able to reduce elevated levels of Hcy and MMA in all the 
studied neurodegenerative disorders. Further studies 
might address the question whether vitamin supplemen-
tation may alter the disease progression with a special 
focus on cognitive impairment.
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